JPS5939831A - Inactivated vaccine of influenzal virus for pig - Google Patents
Inactivated vaccine of influenzal virus for pigInfo
- Publication number
- JPS5939831A JPS5939831A JP14969982A JP14969982A JPS5939831A JP S5939831 A JPS5939831 A JP S5939831A JP 14969982 A JP14969982 A JP 14969982A JP 14969982 A JP14969982 A JP 14969982A JP S5939831 A JPS5939831 A JP S5939831A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- resultant
- influenzal
- amount
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
【発明の詳細な説明】
この発明は、豚のインフルエンザウィルス感染に起因す
る豚の呼吸器病を予防することを目的とする豚用インフ
ルエンザウィルス不活化ワクチンに関するものである。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to an inactivated swine influenza virus vaccine aimed at preventing respiratory diseases in swine caused by swine influenza virus infection.
日本の豚におけるインフルエンザウィルス感染は、19
68年頃よりA香港型(f+)l/L)が知られていた
が、1977年頃よりA豚型(14,Nti H5Vt
’r ) カ侵入し、全国各地で本ウィルスによる呼
吸器病の発生が続いた。われわれも、某集団養豚場にお
ける数年間にわたる呼吸器病に関する調査から、本ウィ
ルスの豚呼吸器病における役割の重要性を明らかにした
。Influenza virus infection in pigs in Japan is 19
Hong Kong type A (f+)l/L) was known from around 1968, but pig type A (14,Nti H5Vt) was known from around 1977.
'r) mosquitoes invaded the country, and outbreaks of respiratory illnesses caused by this virus continued throughout the country. We have also clarified the important role of this virus in swine respiratory disease through several years of research on respiratory disease at a certain group pig farm.
即ち、本ウィルスの感染は、多くの場合、細菌の二次感
染と重なって軽症または重症の呼吸器病を引き起し、食
欲減退、元気消失、肥育除外、重症例の死亡等から養豚
界における本ウィルス感染による損耗は決して少なくな
い。更に本店は養豚業の飼養形態の大型化に伴って、益
−々その被害は大きくなる傾向にあるため、ワクチンに
よる予防法の確立が切望されていたが、現在に至るまで
有効なワクチンの開発はなされていない。In other words, infection with this virus often overlaps with secondary bacterial infection and causes mild or severe respiratory disease, resulting in decreased appetite, loss of energy, exclusion from fattening, and death in severe cases, making it a serious problem in the pig farming industry. The damage caused by this virus infection is not insignificant. Furthermore, as the pig farming industry becomes larger in size, the damage caused by pig farming tends to become more severe, so there has been a strong desire to establish a preventive method using vaccines, but to date there has been no development of an effective vaccine. Not talked about.
一方、インフルエンザウィルスの精製濃縮は、いろいろ
な方法が応用されているが、マクロゴールを用いた例は
未だ知らない。われわれは、lO〜18オ%の比較的高
濃度にマクロゴールを添加する−ことにより、インフル
エンザウィルスの効率的な精製濃縮を容易として、不活
化ワクチンの開発に成功したものであり、呼吸器病発症
豚より分離すれたインフルエンザウィルスをマクロゴー
ル10〜18 ’j; r添加により精製濃縮した不活
化ウィルスを有効成分とする豚用インフルエンザウイル
ス不活化ワクチンを提供するものであり、以下にその詳
細を述べる。On the other hand, various methods have been applied to purify and concentrate influenza viruses, but there are no examples yet of using macrogol. We have succeeded in developing an inactivated vaccine by adding macrogol to a relatively high concentration of 10 to 18% to facilitate the efficient purification and concentration of influenza viruses. We provide an inactivated influenza virus vaccine for swine that contains as an active ingredient an inactivated virus purified and concentrated by adding macrogol 10-18'j;r to influenza viruses isolated from infected pigs. state
まず、A香港型のA/5w1ne /Wadayam
a 15 /68 (J、?N2− )とA/5
w−1,ne/Kyot○ /3 /79 CHtN
t i採取した尿膜膣液に+6.000のマクロゴー
ルを10〜l 8i X添加して2〜18時間かく拝復
、毎分7.000回転で20分間遠心した沈渣をリン酸
緩衝食塩液でぶ〜ふ量に再浮遊し、これにホルマリンを
0.05%%添加して、22℃18時間感作してウィル
スを不活化した後、雨林を混合し、更にリン酸アルミニ
ウムゲルを10迄’l添加して、インフルエンザウィル
ス不活化ワクチンが得られるのであり、このワクチンは
次に示すような性質を有する。First, A Hong Kong type A/5w1ne/Wadayam
a 15 /68 (J,?N2-) and A/5
w-1,ne/Kyot○ /3 /79 CHtN
Add 10~18iX of +6,000 macrogol to the collected allantois-vaginal fluid and leave it for 2~18 hours, centrifuge at 7,000 rpm for 20 minutes, and soak the sediment in phosphate buffered saline. After adding 0.05% formalin and sensitizing at 22°C for 18 hours to inactivate the virus, rainforest was mixed, and aluminum phosphate gel was further added for up to 10 minutes. 1, an inactivated influenza virus vaccine can be obtained, and this vaccine has the following properties.
(1)3適齢マウスの腹腔内に0.51接種して7 F
(間観察するとき、体重の減少を認めず。(1) Inject 0.51 intraperitoneally into 3 appropriate age mice to 7F
(No weight loss was observed during observation.)
また、lΦ日口の採取血清は8倍以上の血球凝集抑制(
以下これをトJ工と略称する)抗体を産生ずる。In addition, the serum collected from lΦHiguchi inhibited hemagglutination by more than 8 times (
(Hereinafter, this will be abbreviated as "ToJ").
(2)H工抗体陰性の2〜4.力月齢の豚に211IQ
宛2〜3週間隔で2回皮下または筋肉内注射すると、豚
は何等の異常も示さず、2回接種後2〜8週目には、4
0〜64Iθ倍の1]工抗体を産生ずる。(2) H-antibody negative 2-4. 211 IQ for a 1 month old pig
When given two subcutaneous or intramuscular injections 2 to 3 weeks apart, pigs do not show any abnormalities, and 2 to 8 weeks after the second vaccination, 4
It produces 0 to 64 Iθ times more 1] engineering antibodies.
(3)これらの免疫豚は、生ウィルスの攻撃、たとえば
、鼻腔内接種等の攻撃試験によって、鼻腔からのウィル
ス回収は、無処置対照豚に比し著しく少なく、感染を防
御することが知られる。(3) When these immunized pigs are challenged with live virus, for example, by intranasal inoculation, virus recovery from the nasal cavity is significantly lower than in untreated control pigs, and it is known that they are protected against infection. .
以上のような豚用インフルエンザウイルス不活化ワクチ
ンの発明は、本ウィルス感染に起因 ゛する豚の呼
吸器病に対して有効で、かつ安全であることから、この
発明の価値は大きいということができる。The above-mentioned invention of an inactivated influenza virus vaccine for swine is effective and safe against respiratory diseases in pigs caused by infection with this virus, so it can be said that this invention has great value. .
以下に実施例を示す。Examples are shown below.
インフルエンザウィルス A/5Wlne/Wada;
yama15/68とA/5w1ne/Kyoto/8
/79をそれぞれ別々に10日発育鶏卵尿膜腔内に接種
し、87℃に2日間−卵後採取した尿膜膣液にす6.0
00のマクロゴールをlv多〆添加して、4℃にて2時
間かく拌感作後、4℃で毎分7.000回転で80層
尿膜膣液の名聞に再浮遊し、ホルマリンを0.05q7
の割合に添加して22℃で18時間感作し、ウィルスを
不活化した。Influenza virus A/5Wlne/Wada;
yama15/68 and A/5w1ne/Kyoto/8
/79 was separately inoculated into the allantoic cavity of a 10-day-old chicken egg, and the allantoic fluid collected after the egg was heated to 87°C for 2 days.
After sensitization by stirring at 4°C for 2 hours, add 0.00 lv of macrogol, resuspend in 80 layers of allantois vaginal fluid at 4°C and 7,000 revolutions per minute, and remove formalin to 0. .05q7
The virus was inactivated by adding the virus at a ratio of 10 to 100 ml and sensitizing it at 22°C for 18 hours.
上記2株の精製濃縮不活化ウィルスを等量混合し、更に
リン酸アルミニウムゲルを10 %7添加して不活化ワ
クチンを得た。Equal amounts of the above two strains of purified, concentrated, and inactivated viruses were mixed, and 10% aluminum phosphate gel was added to obtain an inactivated vaccine.
この不活化ワクチンを豚の皮下または筋肉内に21宛2
〜3週間隔で2回注射すると免疫は6力月以上持続し、
ワクチンを2〜5℃の冷暗所に保存すれば有効期間は1
2力月間であった。Inject this inactivated vaccine subcutaneously or intramuscularly into pigs at 21 to 2
If you give two injections ~3 weeks apart, immunity will last for more than 6 months,
If the vaccine is stored in a cool and dark place at 2 to 5 degrees Celsius, its shelf life is 1.
It was 2 months.
また、このワクチンの安全性および有効性について、次
のような結果を得た。Additionally, the following results were obtained regarding the safety and efficacy of this vaccine.
(1)安全性と免疫の持続について
H工抗体陰性の約2カ月齢の豚lO頭を用い第1表に示
すように、不活化ワクチンを4゜頭に皮下、別の4頭に
筋肉内注射をそれぞれ2週間隔で2回行ない、残り2頭
を無処置対照として同居させ、接種時の反応および臨床
症状を観察したか、注射豚並びに対照豚ともに全く異常
は認められなかった。(1) Regarding safety and duration of immunity, we used 10 pigs of about 2 months old who were negative for H-antibodies and administered the inactivated vaccine subcutaneously to 4 pigs and intramuscularly to another 4 pigs, as shown in Table 1. The injections were performed twice at 2-week intervals, and the remaining two pigs were kept together as untreated controls to observe the reaction and clinical symptoms at the time of inoculation, and no abnormalities were observed in either the injected pigs or the control pigs.
また、接種後2週目、1力月から7力月まで一部採血し
、それぞれのII抗体価を測定し、その成績を第1表に
示したが、少なくとも6力月間は免疫を持続した。In addition, two weeks after vaccination, a portion of blood was collected from the first month to the seventh month, and the respective II antibody titers were measured, and the results are shown in Table 1. It was found that immunity lasted for at least 6 months. .
(2)有効性について
約2カ月齢の抗体陰性豚12頭を供試し、第2表に示す
とおり、不活化ワクチンを4・頭に皮下、別の41頭に
は筋肉内に2週間隔て2回注射後3週目に、それぞれの
免疫原を2群に分け、A香港型とA豚型つィルス%16
”Eより50/’mu液3muを鼻腔内攻撃して10日
間、鼻腔拭い液からのウィルス回収を行い、その結果は
第2表に示したが、ワクチン接種の効果は著しく、前記
安全性とともに有効性をも有することが明らかとなった
。(2) To evaluate efficacy, 12 antibody-negative pigs of approximately 2 months of age were tested. As shown in Table 2, the inactivated vaccine was administered subcutaneously to 4 pigs, and 2 times intramuscularly to another 41 pigs at 2-week intervals. Three weeks after the first injection, each immunogen was divided into two groups: A Hong type and A swine type virus%16.
The virus was recovered from the nasal swab for 10 days after intranasal challenge with 3 mu of 50/'mu solution from E. The results are shown in Table 2. It became clear that it also has effectiveness.
第1表 備考二上段はA豚型、下段はA香港型の抗体価第2表Table 1 Note 2: The upper row shows the antibody titer for A pig type, and the lower row shows the antibody titer for A Hong Kong type.
Claims (1)
マクロゴールを10〜18えγ添加して精製濃縮し、ホ
ルマリンで不活化して得た豚用ワクチン。A vaccine for pigs obtained by adding 10 to 18 g of macrogol to influenza virus grown in the allantoic cavity of embryonated chicken eggs, purifying and concentrating it, and inactivating it with formalin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14969982A JPS5939831A (en) | 1982-08-27 | 1982-08-27 | Inactivated vaccine of influenzal virus for pig |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14969982A JPS5939831A (en) | 1982-08-27 | 1982-08-27 | Inactivated vaccine of influenzal virus for pig |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS5939831A true JPS5939831A (en) | 1984-03-05 |
Family
ID=15480879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP14969982A Pending JPS5939831A (en) | 1982-08-27 | 1982-08-27 | Inactivated vaccine of influenzal virus for pig |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5939831A (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2682966A1 (en) * | 1991-10-29 | 1993-04-30 | Rhone Merieux | PREPARATION OF ANTIGENS AND VACCINES OF MYSTERY DISEASE VIRUS, ANTIGENS AND VACCINES OBTAINED FOR THE PREVENTION OF THIS DISEASE. |
WO1999064570A1 (en) * | 1998-06-12 | 1999-12-16 | Mount Sinai School Of Medicine Of The City University Of New York | Novel methods and interferon deficient substrates for the propagation of viruses |
US6468544B1 (en) | 1998-06-12 | 2002-10-22 | Mount Sinai School Of Medicine Of The City University Of New York | Interferon inducing genetically engineered attenuated viruses |
US7442527B2 (en) | 2000-04-10 | 2008-10-28 | Mount Sinai School Of Medicine Of New York University | Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents |
JP2009026576A (en) * | 2007-07-19 | 2009-02-05 | Denso Wave Inc | Operation switche for portable terminal |
KR101093510B1 (en) | 2010-01-13 | 2011-12-14 | 대한민국(관리부서 : 농림수산식품부 농림수산검역검사본부) | Cell origin inactivated vaccines for the prevention of swine influenza and preparation methods thereof |
US8124101B2 (en) | 2004-06-01 | 2012-02-28 | Mount Sinai School Of Medicine | Genetically engineered swine influenza virus and uses thereof |
US8137676B2 (en) | 2005-02-15 | 2012-03-20 | Mount Sinai School Of Medicine | Genetically engineered equine influenza virus and uses thereof |
US10029005B2 (en) | 2015-02-26 | 2018-07-24 | Boehringer Ingelheim Vetmedica Gmbh | Bivalent swine influenza virus vaccine |
-
1982
- 1982-08-27 JP JP14969982A patent/JPS5939831A/en active Pending
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2682966A1 (en) * | 1991-10-29 | 1993-04-30 | Rhone Merieux | PREPARATION OF ANTIGENS AND VACCINES OF MYSTERY DISEASE VIRUS, ANTIGENS AND VACCINES OBTAINED FOR THE PREVENTION OF THIS DISEASE. |
US8057803B2 (en) | 1998-06-12 | 2011-11-15 | Mount Sinai School Of Medicine | Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals |
WO1999064570A1 (en) * | 1998-06-12 | 1999-12-16 | Mount Sinai School Of Medicine Of The City University Of New York | Novel methods and interferon deficient substrates for the propagation of viruses |
US9352033B2 (en) | 1998-06-12 | 2016-05-31 | Icahn School Of Medicine At Mount Sinai | Methods for the propagation of modified influenza viruses in embryonated eggs |
US6669943B1 (en) | 1998-06-12 | 2003-12-30 | Mount Sinai School Of Medicine Of New York University | Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals |
US6852522B1 (en) | 1998-06-12 | 2005-02-08 | Mount Sinai School Of Medicine Of New York University | Methods and interferon deficient substrates for the propagation of viruses |
US6866853B2 (en) | 1998-06-12 | 2005-03-15 | Mount Sinai School Of Medicine Of New York University | Interferon inducing genetically engineered attenuated viruses |
US7588768B2 (en) | 1998-06-12 | 2009-09-15 | Mount Sinai School Of Medicine Of New York University | Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals |
US8765139B2 (en) | 1998-06-12 | 2014-07-01 | Icahn School Of Medicine At Mount Sinai | Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals |
US7494808B2 (en) | 1998-06-12 | 2009-02-24 | Mount Sinai School Of Medicine Of New York University | Methods and interferon deficient substrates for the propagation of viruses |
US9387240B2 (en) | 1998-06-12 | 2016-07-12 | Icahn School Of Medicine At Mount Sinai | Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals |
US6573079B1 (en) | 1998-06-12 | 2003-06-03 | Mount Sinai School Of Medicine Of New York University | Methods and interferon deficient substrates for the propagation of viruses |
US6468544B1 (en) | 1998-06-12 | 2002-10-22 | Mount Sinai School Of Medicine Of The City University Of New York | Interferon inducing genetically engineered attenuated viruses |
US7442527B2 (en) | 2000-04-10 | 2008-10-28 | Mount Sinai School Of Medicine Of New York University | Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents |
US7833774B2 (en) | 2000-04-10 | 2010-11-16 | Mount Sinai School Of Medicine Of New York University | Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents |
US10543268B2 (en) | 2004-06-01 | 2020-01-28 | Icahn School Of Medicine At Mount Sinai | Genetically engineered swine influenza virus and uses thereof |
US8999352B2 (en) | 2004-06-01 | 2015-04-07 | Icahn School Of Medicine At Mount Sinai | Genetically engineered swine influenza virus and uses thereof |
US8124101B2 (en) | 2004-06-01 | 2012-02-28 | Mount Sinai School Of Medicine | Genetically engineered swine influenza virus and uses thereof |
US9549975B2 (en) | 2004-06-01 | 2017-01-24 | Icahn School Of Medicine At Mount Sinai | Genetically engineered swine influenza virus and uses thereof |
US10098945B2 (en) | 2004-06-01 | 2018-10-16 | Icahn School Of Medicine At Mount Sinai | Genetically engineered swine influenza virus and uses thereof |
US8137676B2 (en) | 2005-02-15 | 2012-03-20 | Mount Sinai School Of Medicine | Genetically engineered equine influenza virus and uses thereof |
JP2009026576A (en) * | 2007-07-19 | 2009-02-05 | Denso Wave Inc | Operation switche for portable terminal |
KR101093510B1 (en) | 2010-01-13 | 2011-12-14 | 대한민국(관리부서 : 농림수산식품부 농림수산검역검사본부) | Cell origin inactivated vaccines for the prevention of swine influenza and preparation methods thereof |
US10029005B2 (en) | 2015-02-26 | 2018-07-24 | Boehringer Ingelheim Vetmedica Gmbh | Bivalent swine influenza virus vaccine |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6919084B2 (en) | Duck pneumovirus and corresponding vaccines | |
US4317811A (en) | Herpes simplex type 1 subunit vaccine | |
DK162421B (en) | DOG COURSE VACCINE, PROCEDURES FOR PRODUCING IT AND VIRUS STEMS FOR USING THE VACCINE | |
JP2009203242A (en) | Multiple and polyvalent dna vaccine in ovo | |
US5807551A (en) | Method to provide artificial passive immunity in birds | |
JPS5939831A (en) | Inactivated vaccine of influenzal virus for pig | |
WO2018000708A1 (en) | Muscovy duck parvovirus subunit vaccine | |
Winterfield et al. | Vaccination against infectious bronchitis and the immunosuppressive effects of infectious bursal disease | |
HULL et al. | Immunization against b virus infection: Preparation of an experimental vaccine | |
JPS62198626A (en) | Vaccine for preventing infectious disease of virus of hemagglutinating encephalomyelitis | |
Randall et al. | The preparation and properties of a purified equine encephalomyelitis vaccine | |
US3518347A (en) | Vaccine for equine influenza | |
Virelizier et al. | The role of humoral immunity in host defence against influenza A infection in mice | |
US3293130A (en) | Panleukopenia vaccine and method for the production thereof | |
CN101732716B (en) | Antigen-antibody complex for preventing and/or treating avian influenza | |
Zinkernagel | Antiviral T-cell memory? | |
CN108018261B (en) | Canine parainfluenza virus strain and application thereof | |
Hale et al. | The Intracranial Toxicity of Influenza Virus for Mice. | |
CN109735504B (en) | Canine distemper virus attenuated vaccine strain and application thereof | |
CN111840532A (en) | Live vaccine for preventing viral infectious diseases | |
JP3945842B2 (en) | Attenuated Newcastle disease virus vaccine | |
JP2521226B2 (en) | Mixed vaccine for dogs | |
KR920005661B1 (en) | Live combination vaccine | |
MXPA96003124A (en) | Vaccine against the newcastle beni disease virus | |
JPS6327437A (en) | Live vaccine for infectious disease of chicken |